Patel Anish

SEC source: 0001415889-24-012652 · form4-05092024_120559.xml · nonDerivative · entry 1

Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,875

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023.

SEC source: 0001415889-24-010831 · form4-04152024_110448.xml · derivative · entry 4

Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 60,717

Underlying: Common Stock · 14,903 shares

Expires 2031-03-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023.

F4 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on August 14, 2021.

SEC source: 0001415889-24-010831 · form4-04152024_110448.xml · nonDerivative · entry 2

Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023.

F2 · price: This transaction was executed in multiple trades at prices ranging from $25.00 to $25.52. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

SEC source: 0001415889-24-010831 · form4-04152024_110448.xml · nonDerivative · entry 1

Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023.

SEC source: 0001415889-24-010676 · form4-04112024_120405.xml · nonDerivative · entry 2

Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,597

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023.

F3 · price: This transaction was executed in multiple trades at prices ranging from $19.245 to $19.49. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

SEC source: 0001415889-24-010676 · form4-04112024_120405.xml · nonDerivative · entry 1

Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,141

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023.

F2 · price: This transaction was executed in multiple trades at prices ranging from $18.19 to $19.15. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

SEC source: 0001415889-24-007457 · form4-03092024_120325.xml · nonDerivative · entry 1

Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,472

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023.

F2 · price: This transaction was executed in multiple trades at prices ranging from $15.19 to $15.97. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

SEC source: 0001415889-24-004026 · form4-02162024_020214.xml · derivative · entry 1

Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 185,000

Underlying: Common Stock · 185,000 shares

Expires 2034-02-12

F1 · derivative.exercise_date: 1/4th of the shares subject to the option will vest on February 13, 2025 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

SEC source: 0001415889-24-003122 · form4-02092024_010243.xml · nonDerivative · entry 1

Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,347

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023.

F2 · price: This transaction was executed in multiple trades at prices ranging from $15.07 to $15.11. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

SEC source: 0001209191-24-002190 · doc4.xml · nonDerivative · entry 1

Patel Anish · CIK 0001967163 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,222

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023.

F2 · price: This transaction was executed in multiple trades at prices ranging from $15.10 to $15.22. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

SEC source: 0001209191-24-000256 · doc4.xml · nonDerivative · entry 3

Patel Anish · CIK 0001967163 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,097

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023.

F3 · price: This transaction was executed in multiple trades at prices ranging from $15.00 to $15.005. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

SEC source: 0001209191-24-000256 · doc4.xml · nonDerivative · entry 2

Patel Anish · CIK 0001967163 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,097

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023.

SEC source: 0001209191-24-000256 · doc4.xml · nonDerivative · entry 1

Patel Anish · CIK 0001967163 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,117

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023.

F2 · price: This transaction was executed in multiple trades at prices ranging from $15.00 to $15.28. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

SEC source: 0001209191-23-059816 · doc4.xml · nonDerivative · entry 2

Patel Anish · CIK 0001967163 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,637

F1 · kind: The sales reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023.

SEC source: 0001209191-23-059816 · doc4.xml · nonDerivative · entry 1

Patel Anish · CIK 0001967163 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,739

F1 · kind: The sales reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023.

F2 · price: This transaction was executed in multiple trades at prices ranging from $15.00 to $15.24. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

SEC source: 0001209191-23-023680 · doc4.xml · derivative · entry 1

Patel Anish · CIK 0001967163 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 206,000

Underlying: Common Stock · 206,000 shares

Expires 2033-04-04

F1 · derivative.exercise_date: 1/4th of the shares subject to the option will vest on February 23, 2024 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date

SEC source: 0001209191-23-013496 · doc4.xml · derivative · entry 5

Patel Anish · CIK 0001967163 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,620

Underlying: Common Stock · 75,620 shares

Expires 2031-03-24

F4 · price: In connection with the Merger, each Enliven stock option that was outstanding immediately prior to the effective time of the Merger was assumed by Imara and became an option to acquire, on the same terms and conditions as were applicable to such Enliven stock option immediately prior to the effective time of the Merger, a number of shares of Imara common stock equal to the number of shares of Enliven common stock subject to the unexercised portion of the Enliven stock option immediately prior to the effective time of the Merger, multiplied by the exchange ratio (rounded down to the nearest whole share number), with an exercise price per share for the options equal to the exercise price per share of such Enliven stock option immediately prior to the effective time of the Merger divided by the exchange ratio (rounded up to the nearest whole cent).

F6 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on August 14, 2021.

SEC source: 0001209191-23-013496 · doc4.xml · derivative · entry 4

Patel Anish · CIK 0001967163 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,827

Underlying: Common Stock · 2,827 shares

Expires 2031-03-24

F4 · price: In connection with the Merger, each Enliven stock option that was outstanding immediately prior to the effective time of the Merger was assumed by Imara and became an option to acquire, on the same terms and conditions as were applicable to such Enliven stock option immediately prior to the effective time of the Merger, a number of shares of Imara common stock equal to the number of shares of Enliven common stock subject to the unexercised portion of the Enliven stock option immediately prior to the effective time of the Merger, multiplied by the exchange ratio (rounded down to the nearest whole share number), with an exercise price per share for the options equal to the exercise price per share of such Enliven stock option immediately prior to the effective time of the Merger divided by the exchange ratio (rounded up to the nearest whole cent).

F5 · derivative.exercise_date: Shares subject to the option vest in 24 equal monthly installments beginning on September 9, 2022.

SEC source: 0001209191-23-013496 · doc4.xml · derivative · entry 3

Patel Anish · CIK 0001967163 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,767

Underlying: Common Stock · 10,767 shares

Expires 2030-06-15

F4 · price: In connection with the Merger, each Enliven stock option that was outstanding immediately prior to the effective time of the Merger was assumed by Imara and became an option to acquire, on the same terms and conditions as were applicable to such Enliven stock option immediately prior to the effective time of the Merger, a number of shares of Imara common stock equal to the number of shares of Enliven common stock subject to the unexercised portion of the Enliven stock option immediately prior to the effective time of the Merger, multiplied by the exchange ratio (rounded down to the nearest whole share number), with an exercise price per share for the options equal to the exercise price per share of such Enliven stock option immediately prior to the effective time of the Merger divided by the exchange ratio (rounded up to the nearest whole cent).

F3 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on May 3, 2020.

SEC source: 0001209191-23-013496 · doc4.xml · nonDerivative · entry 2

Patel Anish · CIK 0001967163 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 394,027

F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of October 13, 2022 (the "Merger Agreement"), by and among Imara Inc. ("Imara"), Enliven Therapeutics, Inc., ("Enliven") and Iguana Merger Sub, Inc., a wholly owned subsidiary of the Issuer (the "Merger Sub"), which provided for the merger of Merger Sub with and into Enliven, with Enliven surviving the merger as a wholly-owned subsidiary of Imara (the "Merger"). At the effective time of the Merger, each share of Enliven common stock was converted into the right to receive a number of shares of Imara common stock equal to an exchange ratio of approximately 0.2951 shares of Imara common stock for each share of Enliven common stock. After completion of the Merger, the combined company will be renamed "Enliven Therapeutics, Inc." and the common stock of the combined company will trade on The Nasdaq Stock Market under the symbol "ELVN."

F2 · ownership.nature: The shares are held by The Patel / Dong Family Trust Dated August 24 2017 for which the reporting person serves as trustee.

SEC source: 0001209191-23-013496 · doc4.xml · nonDerivative · entry 1

Patel Anish · CIK 0001967163 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,722

F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of October 13, 2022 (the "Merger Agreement"), by and among Imara Inc. ("Imara"), Enliven Therapeutics, Inc., ("Enliven") and Iguana Merger Sub, Inc., a wholly owned subsidiary of the Issuer (the "Merger Sub"), which provided for the merger of Merger Sub with and into Enliven, with Enliven surviving the merger as a wholly-owned subsidiary of Imara (the "Merger"). At the effective time of the Merger, each share of Enliven common stock was converted into the right to receive a number of shares of Imara common stock equal to an exchange ratio of approximately 0.2951 shares of Imara common stock for each share of Enliven common stock. After completion of the Merger, the combined company will be renamed "Enliven Therapeutics, Inc." and the common stock of the combined company will trade on The Nasdaq Stock Market under the symbol "ELVN."